GSK plc Sponsored ADR (GSK)
GSK to appeal US judge's Zantac ruling
GSK PLC (LSE:GSK, NYSE:GSK) says it disagrees with a decision by a court judge in the US state of Delaware who has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward. The ruling, from late on Friday by Judge Vivian Medinilla of the Delaware Superior Court, was that expert witnesses can testify in court that the drug may cause cancer.
GSK blood cancer drug nearly halves risk of death in late-stage trial
GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunday.
Glaxo (GSK) Up 1.6% Since Last Earnings Report: Can It Continue?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK development pipeline underrated suggests Deutsche Bank
GSK's development pipeline has lots of underrated potential says Deutsche Bank, which recently hosted a meeting with most of the pharma's top R&D executives. Work needs to be done to rebuild the innovation proposition in the eyes of many investors, but Deutsche Bank sees clear emergent strands of underappreciated potential.
GSK plc: Long-Term Cash Cow
On May 1, London-based GSK published financial results for the first three months of 2024, which pleasantly surprised me. Sales of Jemperli for the first three months of 2024 amounted to about $101 million, up 46.6% from the previous quarter. The company has a rich pipeline of investigational vaccines and drugs, many of which have the potential to become "gold standards" in the fight against various viruses and disorders.
GSK found not guilty in Zantac trial
British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois, US, over its heartburn medication Zantac. A jury determined that Zantac was not responsible for the plaintiff's colon cancer, with the judge rejecting a request for $640 million in damages.
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
GSK's GSK two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints.
GSK Breathes New Life Into Asthma Treatment With Depemokimab
GSK plc has advanced asthma care with their innovative depemokimab therapy, which is an IL-5 inhibitor and offers a long-acting option for severe asthma. Depemokimab demonstrated a significant reduction in asthma exacerbations over 52 weeks in clinical trials. Financially, GSK shows solid earnings growth but has a current ratio below 1, indicating possible liquidity issues.
GSK: Zantac settlement could reach $2bn, says investment bank
GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the investment banking arm of Barclays. Zantac was pulled from the market in 2019 after the US Food and Drug Administration (FDA) found it contained N-nitrosodimethylamine (NDMA), a probable carcinogen.
GSK: Zantac settlement could reach $2bn, says investment bank
GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the investment banking arm of Barclays. Zantac was pulled from the market in 2019 after the US Food and Drug Administration (FDA) found it contained N-nitrosodimethylamine (NDMA), a probable carcinogen.
GSK says late-stage trials of potential blockbuster asthma drug met their goals
GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than £3 billion ($3.8 billion) met their goals.
